Seroatlas · Human Serome Atlas

EGLN2

Prolyl hydroxylase EGLN2

Also known as: EGLN2_HUMAN, HIFPH1, PHD1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q96KS0
Gene
EGLN2
Ensembl
ENSG00000269858
Chromosome
19
Canonical length
407 aa
Protein class
Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm

OverviewNCBI Gene

The hypoxia inducible factor (HIF) is a transcriptional complex that is involved in oxygen homeostasis. At normal oxygen levels, the alpha subunit of HIF is targeted for degration by prolyl hydroxylation. This gene encodes an enzyme responsible for this post-translational modification. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the upstream RAB4B (RAB4B, member RAS oncogene family) gene. [provided by RefSeq, Feb 2011]

Canonical amino-acid sequenceUniProt

407 residues, UniProt reviewed canonical sequence.

>Q96KS0|EGLN2
     1  MDSPCQPQPL SQALPQLPGS SSEPLEPEPG RARMGVESYL PCPLLPSYHC PGVPSEASAG
    61  SGTPRATATS TTASPLRDGF GGQDGGELRP LQSEGAAALV TKGCQRLAAQ GARPEAPKRK
   121  WAEDGGDAPS PSKRPWARQE NQEAEREGGM SCSCSSGSGE ASAGLMEEAL PSAPERLALD
   181  YIVPCMRYYG ICVKDSFLGA ALGGRVLAEV EALKRGGRLR DGQLVSQRAI PPRSIRGDQI
   241  AWVEGHEPGC RSIGALMAHV DAVIRHCAGR LGSYVINGRT KAMVACYPGN GLGYVRHVDN
   301  PHGDGRCITC IYYLNQNWDV KVHGGLLQIF PEGRPVVANI EPLFDRLLIF WSDRRNPHEV
   361  KPAYATRYAI TVWYFDAKER AAAKDKYQLA SGQKGVQVPV SQPPTPT

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against EGLN2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.47
Highest tissue expression
224 nTPM

Expression across tissuesHPA

Tissue

  • testis: 224 nTPM
  • spleen: 113 nTPM
  • basal ganglia: 75 nTPM
  • hippocampal formation: 73 nTPM
  • lung: 72 nTPM
  • choroid plexus: 70 nTPM

Single-cell type

  • platelets: 2.8 nCPM
  • late primary spermatocytes: 2.1 nCPM
  • early spermatids: 1 nCPM
  • lacrimal acinar cells: 0.9 nCPM
  • late spermatids: 0.9 nCPM
  • microglia: 0.8 nCPM

Immune cell

  • neutrophil: 263 nTPM
  • eosinophil: 191 nTPM
  • total PBMC: 110 nTPM
  • naive CD4 T-cell: 106 nTPM
  • memory CD4 T-cell: 102 nTPM
  • T-reg: 100 nTPM

Brain region

  • cerebral cortex: 105 nTPM
  • hippocampal formation: 97 nTPM
  • thalamus: 93 nTPM
  • basal ganglia: 89 nTPM
  • midbrain: 89 nTPM
  • amygdala: 89 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.45
gnomAD pLI
0.72
gnomAD missense Z
1.45
DepMap mean gene effect
-0.16
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of EGLN2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads EGLN2 as an antibody target. Whether an autoantibody or antibody against EGLN2 could matter depends on whether native EGLN2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

EGLN2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label EGLN2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/EGLN2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...